Guidance for best practice for clinical trials, World Health Organisation, 2024

Discussion in 'Trial design including bias, placebo effect' started by Trish, Nov 4, 2024 at 11:07 AM.

Tags:
  1. Trish

    Trish Moderator Staff Member

    Messages:
    55,292
    Location:
    UK
    Moved from News from Cochrane

    https://iris.who.int/bitstream/handle/10665/378782/9789240097711-eng.pdf?sequence=1

    page 8
    The Technical Advisory Group (TAG) for Development of Best Practices for Clinical Trials was constituted through a public call for nominations.
    16 names including Karla Soares-Weisser, Cochrane

    The document was drafted by 2 people, then there were multiple feedback rounds from different groups including the TAG.

    page 12-13 (my bolding)
    page 26 onwards
    2. Key scientific and ethical considerations for clinical trials
    2.1 Good clinical trials are designed to produce scientifically sound answers to relevant questions
    2.1.1 Robust intervention allocation
    about the importance of randomisation
    2.1.2 Blinding/masking of allocated trial intervention (where feasible)
    2.1.3 Appropriate trial population
    2.1.4 Adequate size
    2.1.5 Adherence to allocated trial intervention
    2.1.6 Completeness of follow-up
    Discusses the importance of following up everyone to capture data on non compliance and harms.

    2.1.7 Relevant measures of outcomes, as simple as possible
    Discusses value of standardised core outcomes to enable comparison across trials.
    2.1.8 Proportionate, efficient and reliable capture of data

    2.1.9 Ascertainment of outcomes
    2.1.10 Statistical analysis
    For RCTs, the main analyses should follow the intention-to-treat principle, ...
    Discussion of use of secondary outcomes and subgroup analyses.
    2.1.11 Assessing beneficial and harmful effects of the intervention
    page 33
    2.1.12 Monitoring emerging information on benefits and harms

    page 34
    2.2 Good clinical trials respect the rights and well-being of participants
    2.2.1 Appropriate communication with participants
    About timely and accessible information.
    2.2.2 Relevant consent
    mainly about capacity to give consent and safety.
    2.2.3 Changing consent
    Importance of clarifying with participant what they are withdrawing from, eg treatment, or consent for data to be used...
    page 36
    2.2.4 Implications of changing consent
    2.2.5 Managing the safety of individual participants in the clinical trial
    2.2.6 Communication of new information relevant to the intervention
    up to page 36
     
    Last edited: Nov 4, 2024 at 12:10 PM
    MeSci, Nightsong, Maat and 5 others like this.
  2. Trish

    Trish Moderator Staff Member

    Messages:
    55,292
    Location:
    UK
    Continued from above

    page 37
    2.3 Good clinical trials are collaborative and transparent
    2.3.1 Working in partnership with people and communities
    2.3.2 Collaboration among organizations
    2.3.3 Transparency
    2.4 Good clinical trials are designed to be feasible for their context
    2.4.1 Setting and context
    2.4.2 Use of existing resources
    page 39
    2.5 Good clinical trials manage quality effectively and efficiently
    2.5.1 Good governance
    2.5.2 Protecting trial integrity
    2.5.3 Planning for success and focusing on issues that matter
    2.5.4 Monitoring, auditing and inspection of study quality
    seems to be more concerned with excessive monitoring rather than insufficient monitoring.

    page 42
    3. Guidance on strengthening the clinical trial ecosystem
    Wider issues with equality, funding, oversight, accessiblity at national and international level

    3.1.1 Clinical research governance, funding and policy frameworks
    about priorities and funding
    3.1.2 Regulatory systems
    3.1.3 Ethical oversight
    page 51
    3.2.1 Patient and community engagement
    3.2.2 Collaboration, coordination and networking
    3.2.3 Use of common systems and standards
    3.2.4 Training and mentoring
    3.2.5 Efficiency
    3.2.6 Sustainability
    3.2.7 Innovation
    3.2.8 Transparency

    4.Conclusion
     
    Last edited: Nov 4, 2024 at 12:47 PM
    MeSci, Maat, alktipping and 2 others like this.
  3. Peter Trewhitt

    Peter Trewhitt Senior Member (Voting Rights)

    Messages:
    4,069
    Thank you @Trish for wading through this document, do let us known when you find the caveat ‘except when such trials relate to ME/CFS, then all of these necessary methodological design principles can be thrown out of the window’.
     
  4. Trish

    Trish Moderator Staff Member

    Messages:
    55,292
    Location:
    UK
    Ha, yes, you can see from the bits I've highlighted so far that I'm looking for the smoking gun.
     
    MeSci, Maat, alktipping and 2 others like this.
  5. Trish

    Trish Moderator Staff Member

    Messages:
    55,292
    Location:
    UK
    I've copied rather a lot, and not necessarily the 'best bits'. I intend to go back over it later to weed out a lot of words and home in on bits particularly relevant to clinical trials of psych and behavioural interventions for ME/CFS.

    This was linked on the forum via a Cochrane article promoting the document. I therefore will be looking at it particularly in relation to the Cochrane Larun review of Exercise therapy for CFS, and the trials, particularly PACE that informed it.

    At least that's the plan. If someone else wants to explore this too, all the better.
     
    MeSci, alktipping, bobbler and 2 others like this.
  6. Jonathan Edwards

    Jonathan Edwards Senior Member (Voting Rights)

    Messages:
    15,113
    Location:
    London, UK
    Reposted here:

    If blinding of an allocated trial intervention is not feasible (for example in trials of different types of patient management or surgical procedures), blinded or masked outcome assessment should be pursued for objectively determined outcomes, for example through use of a prospective randomized open-label blinded endpoint (PROBE) design (see also Section 2.1.9 ascertainment of outcomes).

    This suggests some confusion. If an endpoint is truly objective then there is no need to blind or mask. I have never heard of PROBE but it sounds dubious. Usually these acronyms are there to weasel through dodgy practices by making them sound respectable.

    Recommending GRADE isn't good.

    All the right words seem to be there, but the impression given is that as long as everyone follows a mindless recipe all will be fine (and you can cut a few corners if you really have to).
     
  7. Trish

    Trish Moderator Staff Member

    Messages:
    55,292
    Location:
    UK
    That bit puzzled me too.

    More about PROBE:

    . 1992 Aug;1(2):113-9. doi: 10.3109/08037059209077502.
    Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point
    L Hansson 1, T Hedner, B Dahlöf

    Since it would cost £48 to access the full article, I am none the wiser.

    I then found this one:
    • Review
    • Published: 16 January 2009
    Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design
    So we have, according to the WHO document:

    blinded or masked outcome assessment should be pursued for objectively determined outcomes


    and according to the Japanese review:

    Principally, the so-called hard end points, which are judged by objective criteria, should be used as primary end points in order to prevent biases.

    I think there's a confusion over what is meant by objective. Does blinding of the outcome assessors somehow render questionnaire scores objective, or do they mean the actual outcomes have to be objective? In which case there should be no need for the outcome assessors to be blinded.

    Edit to add:
    It seems to me that the originators of PROBE in 1992 thought blinding the outcome assessors rendered the outcomes just as good as those of double blind trials, regardless of whether they were subjective or objective outcomes, which is clearly nonsense.

    By 2009 the Japanese group realised PROBE style studies required objective outcomes to be valid, but didn't go one step further and say if the outcomes are objective, you don't need to blind the assessors.
     
    Last edited: Nov 4, 2024 at 3:37 PM
  8. Jonathan Edwards

    Jonathan Edwards Senior Member (Voting Rights)

    Messages:
    15,113
    Location:
    London, UK
    So the new WHO policy is just turning the handle on half-understood concepts of method and no application of common sense. Par for the course.
     
  9. rvallee

    rvallee Senior Member (Voting Rights)

    Messages:
    13,606
    Location:
    Canada
    That's not what objective means. Doing this does not making an outcome objective, this is ridiculous. It can slightly lower the bias involved, but even then it only can do that, it does not mean that it will, and only slightly.

    Just the same way, let's imagine measuring the length of something. Let's say we don't have a standard measuring device and instead use a sample of guesstimators whose guesses are assessed by a blinded assessor. This does not make the guesstimates objective. Everyone involved in making the quoted statement above understands this. And yet they put this ridiculous notion that they can do that out of questionnaires that have layers and layers of biases and uncertainty baked into the process.
    And in behavioral and psychological trials the literal aim of the interventions is to influence the participants' responses. So this completely negates any and all attempts at mitigating the influence of bias, because it consists of targeted bias. It's like building a submarine that can reach the Mariana trench, but has a single porthole with a mosquito net. It doesn't matter if the porthole is small.

    There is also the usual problem where they talk of randomized clinical trials, used the acronym RCT, where the C is typically meant to stand for controlled. This only confuses the issue further, the ambiguity is everywhere. And they do this in what is supposed to be a clarifying document. Mercy.
    As we know, and they know, the entire body of evidence-based medicine in clinical psychology abuses this. It's made of nothing but that, because the primary objectives always fail, and they always fall back onto secondary assessments. This is something that Cochrane abuses the hell out of. The entire body of evidence for psychosomatic medicine depends wholly on this, so this is common practice. They can write it down in black and white all they want, they exempt the contexts in which it's needed the most. Fake rules made from fake standards leading to fake results.
    Another very problematic idea since many trials don't even reach statistical significance and the interventions are still recommended, this is common in psychological interventions, basically the norm. They can write it down all they want, they cannot not know that this is standard practice and that they won't be doing anything to change that.
    It's laughable to have this while organizations like Cochrane simply insist on ignoring exactly that. For years all we've heard from the trialists is that they don't see any harm in their trials and clinics and that's final, any data outside of this context is invalid. Write it down all you want, those are fake rules because they are exempted in exactly the cases where it's needed the most.

    None of this matters if the rules are not enforced as intended. But this invalidates all psychosomatic ideology and most evidence-based medicine so all they do is write it down and pretend like they're following any of this. This entire way of doing things is invalid, completely unreliable. It's like children play-acting being at work.

    Nothing will change in the future, and none of the past errors will be recontextualized. This is a completely empty set of fantasy rules. Like a non-binding code of ethics.
     
    Last edited: Nov 4, 2024 at 4:22 PM
  10. rvallee

    rvallee Senior Member (Voting Rights)

    Messages:
    13,606
    Location:
    Canada
    I can't find any other way to read this but "the standard in clinical practice is very low, so let's have the same standard in research". Of course it lowers costs. And of course it makes results closer to real-world, where a scientific approach is not possible. This is exactly what you don't want. This makes as much sense as arguing to build semiconductors in standard rooms because they will not be used in clean rooms. Good grief they are abandoning all sense and reason.

    One of the most basic standards of scientific experiments is for "all other things being equal", that you make sure that you are testing one and only one thing influences the outcome. But here they basically prefer the alternative standard of "you know what? let's just not bother with that and go with what we prefer the outcomes to be".

    The death of expertise and reason rolled into one. It's not even novel either. It's literally abandoning the only standard that has ever reliably worked: the scientific method. They are literally advising to just not bother with any of that. Just wing it.
     
  11. rvallee

    rvallee Senior Member (Voting Rights)

    Messages:
    13,606
    Location:
    Canada
    I wonder what's Cochrane's stance on this. "Just putting out there to look good, we don't intend and never meant to follow any of this"? It's for others? Even though basically no one will actually respect this, neither spirit nor word? What is good for, then? Just virtue signaling?

    Would it be worth writing to Cochrane and Bastian about all the points they are explicitly ignoring with the exercise review? I know it wouldn't make any difference, but it would expose the hypocrisy and futility of this organization and their pretend standards. Just to put it out there in writing.
     
  12. bobbler

    bobbler Senior Member (Voting Rights)

    Messages:
    3,689
    the main thing with blinding of course is if you have 50-50 controls-treated then there is no incentive to bumping scores (even if done 'unconsciously') because really the important thing should be treatment increase - [minus] controls increase, so bumping up the score is just as likely to be 'subtracted' from your outcome as added to it if you don't know who is who.

    I'm not quite sure how you can claim this level of blindness however when there are likely to be other 'hallmarks' like a surgical scar or for those who've done robotic CBT it'll be really blinking obvious (oh I shouldn't whinge, phrase positively, certain programmed phrases). And of course the biggie is how incestuous some areas are and how dominant the hierarchy is - so how independent can people really be if:

    - they are in the same clinic
    - they are in the same hospital
    - there is overlap of other staff
    - they are at conferences or other small meetings which might be regular with other people from the same niche
    - they all think the same way/have the same bias (hence the objective measures issue for certain areas because some seem to confuse 'saying the right thing' with 'being better')
    - and then you add in the above and issues with perceived threats for the patient (these people will be reporting back and writing letters that will affect my employers and GP and access to things)... I think being in a visibly different place, with it being made clear there is no way things will be fed back to those delivering not just the trial but potentially their 'care' in such a way that would indeed 100% reassure (does that exist? given the risk = impact vs likelihood, and you can maybe try and reassure on likelihood but that impact bit... without big change to culture and not just laws/rules but being able to make sure they are implemented..)
     
    alktipping and Peter Trewhitt like this.
  13. Maat

    Maat Senior Member (Voting Rights)

    Messages:
    424
    Crikey @Trish what a herculean task! :laugh: you're definitely not pacing. I downloaded it from the Cochrane thread, saw it was yet another single line space 70 odd page document to plough through and thought - hell no! Safety, safety, safety. The WHO have been highlighting this since 2004.
     
  14. Trish

    Trish Moderator Staff Member

    Messages:
    55,292
    Location:
    UK
    I haven't read most of it, just skimmed and copied headings.
     
    alktipping, Peter Trewhitt and Maat like this.

Share This Page